
Aflac (AFL) · Insurance
Aflac Q2 2026 earnings: summary, key numbers & outlook
Results filed 6 Aug 2026 · Quarter ended 30 Jun 2026
Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
Aflac Japan's new Anshin Palette medical and refreshed Tsumitasu life products drove growth, offsetting a high Miraito cancer comparison, while U.S. sales gained from group voluntary benefits and network dental and vision.
Aflac's product launches in Japan are the main business story. Anshin Palette, a new medical insurance product launched in December 2025, and the refreshed Tsumitasu savings-type life insurance grew strongly. Japan sales fell 5.6% for the quarter only because Miraito cancer insurance, launched in March 2025, set a high bar. In the U.S., sales rose 2.6%, helped by group voluntary benefits and network dental and vision products.
Management is steering toward more profitable growth, more reinsurance in Japan, and a push to get brokers to adopt network dental in the second half. Aflac Japan's reinsurance target is now up to 30% of FSA reserves, aiming for a higher return on equity. The tension is that new products are bringing somewhat elevated lapse and reissue activity in Japan, while U.S. premium growth for 2026 is now expected just below its guided range.
No call transcript for this quarter, so this summary also draws on: The Motley Fool ↗.
Key numbers
- Total revenues · GAAP
- $4.1 billion
- Net earnings · GAAP
- $825 million
- Net earnings per diluted share · GAAP
- $1.63
- Adjusted earnings per diluted share · non-GAAP
- $1.75
- Adjusted earnings · non-GAAP
- $883 million
down 1.0% from a year ago
up from $599 million a year ago
up from $1.11 a year ago
down 1.7% from a year ago
down 7.7% from a year ago
| Segment or metric | Value | Change |
|---|---|---|
| Aflac Japan new annualized premium sales | ¥19.6 billion | down 5.6% |
| Aflac U.S. sales | $349 million | up 2.6% |
| Aflac Japan premium persistency | 92.7% | down 100 bps |
| Aflac U.S. persistency | 79.4% | up 20 bps |
Where each number comes from
- Total revenues: “Total revenues were $4.1 billion, which was a 1.0% decrease year over year.”
- Net earnings: “Net earnings were $825 million, or $1.63 per diluted share, compared with $599 million, or $1.11 per diluted share a year ago.”
- Net earnings per diluted share: “Net earnings were $825 million, or $1.63 per diluted share, compared with $599 million, or $1.11 per diluted share a year ago.”
- Adjusted earnings per diluted share: “Adjusted earnings per diluted share* decreased 1.7% to $1.75.”
- Adjusted earnings: “Adjusted earnings* were $883 million, compared with $957 million a year ago, reflecting a decrease of 7.7%.”
- Aflac Japan new annualized premium sales: “total new annualized premium sales (sales) decreased 5.6% to ¥19.6 billion, or $123 million, reflecting a high prior-year sales baseline for Miraito cancer insurance”
- Aflac U.S. sales: “Aflac U.S. sales increased 2.6% in the quarter to $349 million, primarily benefiting from sales of group voluntary benefits and network dental and vision products.”
- Aflac Japan premium persistency: “Persistency remained solid and in line with our expectations at 92.7%.”
- Aflac U.S. persistency: “Premium persistency remained solid at 79.4%, up 20 basis points year over year.”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
| From the filing | Q2 2026 | vs year ago | vs last quarter |
|---|---|---|---|
| Revenue | $4.1B | −1.0% | −5.3% |
| Net income | $825.0M | +37.7% | −19.0% |
| Diluted EPS | $1.63 | +46.8% | −17.7% |
Calculated by code from XBRL, not by the model.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Aflac Japan benefit ratio, high end of range | full year 2026 | 60% to 63% |
| Aflac Japan expense ratio | 2026 | 20% - 23% |
| Aflac Japan pretax profit margin | 2026 | 33% - 36% |
| Aflac U.S. benefit ratio | 2026 | 48% - 52% |
| Aflac U.S. expense ratio | 2026 | 36% - 39% |
| Aflac U.S. pretax profit margin | 2026 | 17% - 20% |
| Aflac U.S. net earned premium growth | 2026 | just below our guidance range of 3% to 6% |
| Aflac U.S. net earned premium CAGR | 2025-2027 | 3% to 6% |
Key takeaways
Japan's new products offset a tough Miraito comparison
Japan sales fell 5.6% to ¥19.6 billion because Miraito cancer insurance launched in March 2025. Strong growth in the refreshed Tsumitasu and Anshin Palette partly offset that, and first-half sales rose 7.0%.
U.S. sales driven by group and network dental
Aflac U.S. sales increased 2.6% to $349 million, mainly from group voluntary benefits and network dental and vision products. This shows the U.S. business moving toward employer-sponsored bundles.
Japan reinsurance target raised to 30% of FSA reserves
Aflac Japan moved from an internal target of up to 10% of U.S. GAAP assets to up to 30% of FSA reserves. Management says this reduces risk, improves balance sheet efficiency and should lift ROE.
New products create elevated lapse and reissue activity
Japan persistency was 92.7%, with somewhat elevated lapse and reissue activity on recently launched products as coverage options expanded. Lapses on the first sector savings block stayed low despite higher yen interest rates.
U.S. premium growth guided just below range
Management now expects 2026 U.S. net earned premium growth just below its 3% to 6% range, versus the low end before. It still expects the 2025-2027 compound growth rate to land within that range.
Charts
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $5.4B * |
| Q1 2025 | $3.4B |
| Q2 2025 | $4.2B |
| Q3 2025 | $4.7B |
| Q4 2025 | $4.9B * |
| Q1 2026 | $4.3B |
| Q2 2026 | $4.1B |
| Q3 2026 | $3.3B |
Data
| Q1 2025 | $0.05 |
| Q2 2025 | $1.11 |
| Q3 2025 | $3.08 |
| Q1 2026 | $1.98 |
| Q2 2026 | $1.63 |
| Q3 2026 | $0.61 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Questions
Which products drove Aflac Japan's sales this quarter?
Refreshed Tsumitasu savings-type life insurance and Anshin Palette, a medical insurance product launched in December 2025, grew strongly. Miraito cancer insurance, launched in March 2025, faced a high prior-year baseline.
What is driving Aflac U.S. sales growth?
U.S. sales rose 2.6% to $349 million, mainly from group voluntary benefits and network dental and vision products. Management plans a stronger second-half push to get brokers to adopt network dental.
How is Aflac changing its reinsurance strategy in Japan?
Aflac Japan raised its reinsurance target to up to 30% of FSA reserves, replacing an internal target of up to 10% of U.S. GAAP assets. Management says it should reduce risk, improve balance sheet efficiency and raise ROE.
Is customer retention a concern in Japan?
Persistency was 92.7%, in line with expectations, with somewhat elevated lapse and reissue activity on newly launched products. Lapses on the first sector savings block remained low despite higher yen interest rates.
How did Aflac change its U.S. premium outlook?
It now expects 2026 net earned premium growth just below the 3% to 6% guidance range, versus the low end of the range previously. It still expects the 2025-2027 compound growth rate within the range.
Documents
SEC filing